Kapitalo Investimentos Ltda Acquires Shares of 20,134 Exelixis, Inc. (NASDAQ:EXEL)

Kapitalo Investimentos Ltda bought a new position in Exelixis, Inc. (NASDAQ:EXEL) in the 3rd quarter, HoldingsChannel.com reports. The firm bought 20,134 shares of the biotechnology company’s stock, valued at approximately $522,000.

Several other institutional investors have also recently made changes to their positions in the company. Fisher Asset Management LLC boosted its holdings in Exelixis by 232.6% during the fourth quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 728 shares during the last quarter. Rise Advisors LLC bought a new position in shares of Exelixis during the 1st quarter worth approximately $28,000. Park Place Capital Corp bought a new position in shares of Exelixis during the 2nd quarter worth approximately $45,000. GAMMA Investing LLC boosted its stake in shares of Exelixis by 107.9% in the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after buying an additional 1,041 shares during the last quarter. Finally, EntryPoint Capital LLC grew its holdings in shares of Exelixis by 537.2% in the first quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 1,746 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on EXEL. Bank of America boosted their price objective on Exelixis from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday. Morgan Stanley boosted their price target on shares of Exelixis from $26.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, October 11th. HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Exelixis in a research report on Wednesday, September 18th. UBS Group initiated coverage on shares of Exelixis in a research report on Thursday, September 19th. They issued a “neutral” rating and a $30.00 price objective on the stock. Finally, Truist Financial reissued a “buy” rating and set a $33.00 target price (up from $32.00) on shares of Exelixis in a research report on Thursday, August 8th. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $28.43.

Exelixis Price Performance

Shares of EXEL stock opened at $28.50 on Wednesday. The stock has a market capitalization of $8.64 billion, a price-to-earnings ratio of 44.53, a PEG ratio of 0.54 and a beta of 0.54. The company’s fifty day simple moving average is $26.29 and its two-hundred day simple moving average is $23.72. Exelixis, Inc. has a 1 year low of $18.64 and a 1 year high of $28.99.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.44. The company had revenue of $637.18 million during the quarter, compared to analysts’ expectations of $468.21 million. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. Equities research analysts anticipate that Exelixis, Inc. will post 1.59 EPS for the current year.

Insider Activity

In other news, CFO Christopher J. Senner sold 125,000 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $27.19, for a total value of $3,398,750.00. Following the completion of the transaction, the chief financial officer now directly owns 721,680 shares in the company, valued at approximately $19,622,479.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Christopher J. Senner sold 125,000 shares of the company’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $27.19, for a total value of $3,398,750.00. Following the transaction, the chief financial officer now owns 721,680 shares of the company’s stock, valued at approximately $19,622,479.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Maria C. Freire sold 8,250 shares of Exelixis stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $26.56, for a total value of $219,120.00. Following the sale, the director now directly owns 91,007 shares of the company’s stock, valued at $2,417,145.92. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 327,858 shares of company stock worth $8,640,129 over the last ninety days. Company insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.